Monoclonal Antibody Administration on Hold from FDA

The FDA has instructed to pause administration of Regen-COV monoclonal antibodies because they are not sure of the effectiveness against the new variants like Omicron. Once they come out with updated guidance we will have more information. Until then, Tarrytown Pharmacy will no longer be administering monoclonal antibodies. Thank you for your patience as we continue to care for the community.

Monoclonal Antibodies

COVID-19 Antibody Treatment (REGEN-COV™)

The FDA has put a pause on administration until more data is available with variants circulating the us. these are not available at this time.

The Process:

* Complete the form above to determine if you are eligible for treatment with mAb

* Our pharmacist staff will review your request and then contact you to confirm appropriateness of therapy, and then schedule treatment

* You will receive an email confirmation with your appointment date, time, and instructions for treatment administration

* Park at our dedicated curbside check-in 5 - 10 minutes prior to your appointment time, and call the check-in number on the sign

* Tarrytown Staff will come out to your vehicle and start your visit, which will include treatment and observation

* Treatment is covered by Medicare Part B. If you don't have insurance, there will be no cost to you, because we will apply to a program for uninsured to cover the cost of treatment.


Monoclonal antibodies (mAb) are a new treatment option for COVID-19 which has been given emergency use authorization (EUA) by the FDA. Monoclonal antibodies are designed in a laboratory to do what our own natural antibodies do, only better. Antibodies are what our body makes on its own to identify and fight infection. The reason we might require treatment with monoclonal antibodies, or mAbs, is that our body may not recognize this new virus SARS-Cov-2 which causes COVID-19. Treatment with mAbs requires direct administration to patients via IV infusion or injection under the skin (subcutaneously). When receiving treatment with mAbs, our bodies can very quickly recognize and fight COVID-19 infection. This is why mAb treatment may help recently exposed or infected patients who are at high risk for serious symptoms or having to stay in the hospital.

mAb treatment for COVID-19 is different from a COVID-19 vaccine. A vaccine causes your body’s natural immune response to turn on, but the process of asking your body to make antibodies or biological markers to identify a certain infection can take weeks. Some vaccines for COVID-19 require two shots, so your body can develop its own immune response to the disease, and these vaccines are highly effective. But if you already have the virus, mAb treatment quickly gives your body the antibodies it needs to protect itself. (1)

Works Cited

(1). Assistant Secretary for
Public Affairs (ASPA). “Monoclonal Antibodies for High-Risk COVID-19 Positive
Patients.”, 24 Aug. 2021,